An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas

Figure 3

Stratification analysis based on clinicopathological and molecular information. (a) The forest plot for survival analysis of the risk signature in patients with female or male, younger or older, WHO grade II or WHO grade III, no chemotherapy or chemotherapy, no radiotherapy or radiotherapy, 1p19q noncodeletion or 1p19q codeletion, and unmethylated MGMT promoter or methylated MGMT promoter. The risk score was grouped by tumor grade (b) and 1p19q codeletion status (c).

(a)

(b)

(c)